AU2001289641A1 - Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses - Google Patents

Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses

Info

Publication number
AU2001289641A1
AU2001289641A1 AU2001289641A AU8964101A AU2001289641A1 AU 2001289641 A1 AU2001289641 A1 AU 2001289641A1 AU 2001289641 A AU2001289641 A AU 2001289641A AU 8964101 A AU8964101 A AU 8964101A AU 2001289641 A1 AU2001289641 A1 AU 2001289641A1
Authority
AU
Australia
Prior art keywords
fragments
derivatives
illnesses
producing
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289641A
Inventor
Knut Adermann
Jose-Ramon Conejo-Garcia
Wolf-Georg Forssmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPF Pharmaceuticals GmbH
Original Assignee
IPF Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPF Pharmaceuticals GmbH filed Critical IPF Pharmaceuticals GmbH
Publication of AU2001289641A1 publication Critical patent/AU2001289641A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Peptides (I) of the defensin type, are new. New peptides (I) have formula (F1). ZN-C-X m-X 1-X-C-X 2-X n-C-X-X-X-X 3-XO-C-X p-C-C-ZC (F1) ZN and ZC : 1 - 30 amino acid (aa) residues; X : any aa; X many 3 - 6 aa; X n2 - 3 aa; X o5 - 9 aa; X p4 - 6 aa; X 1G, A or P; X 2R, K, W, Q or A; X 3E or H. Independent claims are also included for the following: (1) cyclic, amidated, acetylated, sulfated, phosphorylated, glycosylated and oxidized derivatives and fragments of (I), with similar biological activity; (2) methods for preparing (I), their derivatives or fragments; and (3) nucleic acid (II) that encodes one or more of (I), their derivatives or fragments. ACTIVITY : Antibacterial; antiinfertility; contraceptive. The peptide designated hBD17 TPGGTQRCWNLYGKCRYRCSKKERVYVYCINNKMCCVKPKYQPKERWWPF was positive in a radial diffusion test against Escherichia coli, Staphylococcus carnosusand Saccharomyces cerevisiae, and against S. carnosushad MIC below 25 Microg/ml. MECHANISM OF ACTION : Peptide therapy.
AU2001289641A 2000-07-11 2001-07-11 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses Abandoned AU2001289641A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033505.5 2000-07-11
DE10033505 2000-07-11
PCT/EP2001/007973 WO2002004487A2 (en) 2000-07-11 2001-07-11 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses

Publications (1)

Publication Number Publication Date
AU2001289641A1 true AU2001289641A1 (en) 2002-01-21

Family

ID=7648436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289641A Abandoned AU2001289641A1 (en) 2000-07-11 2001-07-11 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses

Country Status (11)

Country Link
US (2) US20040116652A1 (en)
EP (2) EP1887015A3 (en)
JP (1) JP2004504017A (en)
AT (1) ATE373091T1 (en)
AU (1) AU2001289641A1 (en)
CA (1) CA2427066A1 (en)
DE (1) DE50113010D1 (en)
DK (1) DK1299541T3 (en)
ES (1) ES2197840T3 (en)
PT (1) PT1299541E (en)
WO (1) WO2002004487A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
EP1878796A3 (en) * 1999-11-30 2008-01-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2001275208A1 (en) * 2000-06-01 2001-12-11 University Of Iowa Research Foundation Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide
AU2002227925A1 (en) * 2000-11-14 2002-05-27 Ipf Pharmaceuticals Gmbh Human beta-defensin-3
JP2006514106A (en) * 2002-12-19 2006-04-27 ヒルマン，イチャク Disease treatment with antibacterial peptide inhibitors
GB0300718D0 (en) * 2003-01-13 2003-02-12 Ares Trading Sa Proteins
FR2879203A1 (en) * 2004-12-09 2006-06-16 Univ Rennes I Etablissement Pu ANTIMICROBIAL PEPTIDES, POLYPEPTIDES COMPRISING SAID PEPTIDES, PROCESSES FOR PREPARING THEM, GENES ENCODING THE SAME, VECTORS, PROCESSED ORGANISMS AND COMPOSITIONS CONTAINING SAME
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
CN102198264B (en) * 2010-03-23 2013-10-09 中国科学院上海生命科学研究院 Beta-defensin 15 of specific antibacterial peptides of rat epididymis and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69831084T2 (en) * 1997-09-10 2006-06-01 Zymogenetics, Inc., Seattle Beta-defensins
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
EP1068232B1 (en) * 1999-02-01 2005-03-23 Schering Aktiengesellschaft Human antibiotic protein
WO2001049702A1 (en) * 2000-01-05 2001-07-12 Emory University Epididymal antimicrobial peptides

Also Published As

Publication number Publication date
ATE373091T1 (en) 2007-09-15
EP1299541B1 (en) 2007-09-12
CA2427066A1 (en) 2003-02-24
JP2004504017A (en) 2004-02-12
ES2197840T3 (en) 2008-03-16
US20090124541A1 (en) 2009-05-14
DK1299541T3 (en) 2008-01-21
ES2197840T1 (en) 2004-01-16
EP1887015A2 (en) 2008-02-13
WO2002004487A2 (en) 2002-01-17
DE50113010D1 (en) 2007-10-25
WO2002004487A3 (en) 2002-09-19
PT1299541E (en) 2007-10-01
EP1887015A3 (en) 2008-05-07
EP1299541A2 (en) 2003-04-09
US20040116652A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
CA2032059C (en) Wound treatment employing biologically active peptides
AU2001289641A1 (en) Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses
DK1025124T3 (en) Human interferon-alpha analogs with low toxicity
CA2158058A1 (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
ATE108662T1 (en) ANTIMICROBIAL PEPTIDES, COMPOSITIONS CONTAINING SAME AND USES THEREOF.
EP1319023B8 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
JP2005506300A5 (en)
JPH07501519A (en) Bioactive amphipathic peptide compositions and their uses
AU2003260286A1 (en) Collectin-complement activating protein chimeras
Schrimsher et al. Characterization of human and mouse granulocyte-macrophage-colony-stimulating factors derived from Escherichia coli
ATE400294T1 (en) NEW ANTIMICROBIAL POLYPEPTIDES AND METHODS FOR USE THEREOF.
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
WO2002096467A3 (en) Pharmaceutical use for secreted bacterial effector proteins
EP1281763A3 (en) Early growth response-1 (EGR-1) transcription factor
AU7791398A (en) Antimicrobial peptides derived from ubiquicidine
JPH07502979A (en) Prevention and treatment of harmful conditions in the oral cavity using bioactive peptides
JPH07501820A (en) Compositions and treatments with bioactive peptides and chelating agents
WO2001034640A3 (en) Peptide (virip) which inhibits a circulating virus in humans and the use thereof
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
WO1991017760A1 (en) Composition of and treatment with biologically active peptides having d-amino acid residues
ES2188653T3 (en) VARIATIONS OF HUMAN DNASA I.
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
WO2004000870A3 (en) Two synthetic peptides for treatment and prevention of cancers
WO2002100897A3 (en) Brca1/acc alpha molecular complexes, diagnostic and therapeutic applications
CN116715748A (en) LPS targeting peptide based on specific gram-negative bacteria and application thereof